Trial Profile

A Phase II Study of Lenalidomide (Revlimid) in Combination with Rituximab as Initial Treatment for Patients with Indolent Non-Hodgkin's Lymphoma (NHL)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Rituximab
Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Registrational; Therapeutic Use

Most Recent Events

15 Sep 2020 Results (n=79) published in the Blood.
15 Jul 2020 Status changed from active, no longer recruiting to completed.
28 Dec 2019 Planned primary completion date changed from 30 Jun 2019 to 30 Jun 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com